Search Result

Pathways Recommended:	Anti-infection

Results for "

MRSA infection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminoacyl-tRNA Synthetase (4) Amyloid-β (5) Antibiotic (29) Apoptosis (1) Autophagy (1) Bacterial (79) Dihydrofolate reductase (DHFR) (2) DNA/RNA Synthesis (4) Endogenous Metabolite (1) Fungal (8) HIV (1) Influenza Virus (1) Monoamine Oxidase (1) PPAR (1) Proteasome (5) Pyruvate Kinase (1) Reactive Oxygen Species (ROS) (9) Reference Standards (7) SARS-CoV (1) Toll-like Receptor (TLR) (2) Topoisomerase (3) Tyrosinase (1)
By Research Areas:	Cancer (8) Endocrinology (9) Infection (82) Inflammation/Immunology (8) Neurological Disease (6)

By Targets:

Aminoacyl-tRNA Synthetase (4)

Amyloid-β (5)

Antibiotic (29)

Apoptosis (1)

Autophagy (1)

Bacterial (79)

Dihydrofolate reductase (DHFR) (2)

DNA/RNA Synthesis (4)

Endogenous Metabolite (1)

Fungal (8)

HIV (1)

Influenza Virus (1)

Monoamine Oxidase (1)

PPAR (1)

Proteasome (5)

Pyruvate Kinase (1)

Reactive Oxygen Species (ROS) (9)

Reference Standards (7)

SARS-CoV (1)

Toll-like Receptor (TLR) (2)

Topoisomerase (3)

Tyrosinase (1)

By Research Areas:

Cancer (8)

Endocrinology (9)

Infection (82)

Inflammation/Immunology (8)

Neurological Disease (6)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14737

Ceftaroline fosamil 2 Publications Verification TAK-599; PPI0903	Bacterial Antibiotic	Infection
Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection .

HY-14784

Bederocin REP8839	Bacterial	Infection
Bederocin (REP8839) is a Methionyl-tRNA synthetase inhibitor. Bederocin can be used in research of bacterial infection, including S. aureus and MRSA .

HY-119123A

Voxvoganan trihydrochloride LTX-109 trihydrochloride	Fungal Bacterial	Infection
Voxvoganan (LTX-109) trihydrochloride, a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan trihydrochloride can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA .

HY-175338

Anti-MRSA agent 34	Bacterial	Infection
Anti-MRSA agent 34 (Compound 6) is an antimicrobial agent targeting methicillin-resistant Staphylococcus aureus (MRSA) (MIC=14 μg/mL). Anti-MRSA agent 34 is promising for research of microbial infection .

HY-178493

Anti-MRSA agent 37	Bacterial	Infection
Anti-MRSA agent 37 (Compound 5B) is an antibacterial agent against methicillin-resistant Staphylococcus aureus (MRSA) (MIC=0.25-0.5 μg/mL). Anti-MRSA agent 37 inhibits biofilm formation, disrupts cell wall integrit, attacks cell membrane and induces oxidative stress. Anti-MRSA agent 37 is promising for research of MRSA-related diseases such as skin infections .

HY-14737R

Ceftaroline fosamil (Standard) TAK-599 (Standard); PPI0903 (Standard)	Reference Standards Bacterial Antibiotic	Infection
Ceftaroline fosamil (Standard) is the analytical standard of Ceftaroline fosamil. This product is intended for research and analytical applications. Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection[1][2][3].

HY-14738

Ceftaroline fosamil (inner) TAK-599 free acid; PPI0903 free acid	Bacterial Antibiotic	Infection
Ceftaroline fosamil (inner) (TAK-599 free acid), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil (inner) can be used for the research of MRSA infection .

HY-178476

Anti-MRSA agent 36	Bacterial Reactive Oxygen Species (ROS)	Infection
Anti-MRSA agent 36 (Compound III13) is an antibacterial agent with strong anti *MRSA* activity (MIC = 1 μg/mL). Anti-MRSA agent 36 targets phosphatidylglycerol (PG) on bacterial membranes, disrupting membrane integrity, leading to DNA leakage and increased ROS. Anti-MRSA agent 36 has advantages such as low cytotoxicity, low hemolysis, difficulty in inducing drug resistance, and good plasma stability. Anti-MRSA agent 36 can be used for the study of skin abscess and systemic infection models .

HY-178513

Anti-MRSA agent 38	Bacterial Reactive Oxygen Species (ROS)	Infection
Anti-MRSA agent 38 is a broad-spectrum antibacterial agent (MIC = 0.0625-2 µg/mL). Anti-MRSA agent 38 can inhibit ribosomal protein synthesis. Anti-MRSA agent 38 exerts multiple bactericidal effects by disrupting bacterial membrane structure and inducing ROS accumulation. Anti-MRSA agent 38 can selectively kill tumor cells, such as HGC-27 (IC₅₀ = 0.86 µM), MRC-5 (IC₅₀ = 5.52 µM), and RPC (IC₅₀ = 6.09 µM) cells. Anti-MRSA agent 38 can be used to study infectious diseases such as bacterial infection .

HY-119123

Voxvoganan LTX-109	Fungal Bacterial	Infection
Voxvoganan (LTX-109), a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA .

HY-P5545

Lynronne-1	Bacterial	Infection
Lynronne-1 is an antimicrobial peptide. Lynronne-1 is active against Gram-positive bacterials, including MDR strains (MIC: 8-32 μg/mL for methicillin-resistant MRSA strains). Lynronne-1 reduces the bacterial load in MRSA infected wound murine model. Lynronne-1 is also effective against P. aeruginosa infection .

HY-P5547

Lynronne-3	Bacterial	Infection
Lynronne-3 is an antimicrobial peptide. Lynronne-1 is active against Gram-positive bacterials, including MDR strains (MIC: 32-128 μg/mL for methicillin-resistant MRSA strains). Lynronne-3 is also effective against P. aeruginosa infection

HY-P5546

Lynronne-2	Bacterial	Infection
Lynronne-2 is an antimicrobial peptide. Lynronne-1 is active against Gram-positive bacterials, including MDR strains (MIC: 32-256 μg/mL for methicillin-resistant MRSA strains). Lynronne-2 is also effective against P. aeruginosa infection

HY-157482

EBP-59	Bacterial	Infection
EBP-59 is a bacterial inhibitor with antibiofilm activity against Gram-positive bacteria. EBP-59 is effective against Staphylococcus aureus and MRSA (methicillin–resistant staphylococcus aureus). EBP-59 can be used to study bacterial infections .

HY-W904855

Apicidin D2	Endogenous Metabolite Bacterial	Infection
Apicidin D2 (Compound 4), a fungal metabolite, is a Accessory gene regulator A (AgrA) quorum-sensing inhibitor. Apicidin D2 has anti-virulence activity. Apicidin D2 suppresses MRSA agr activation and shows potent inhibitory activities against all agr types in a nonbiocidal manner. Apicidin D2 can be used for MRSA infections research .

HY-N9690

Longistyline A Longistylin A	Bacterial	Infection Neurological Disease
Longistyline A (Longistylin A) is a natural stilbene, it can be isolated from leaves of Cajanus cajan. Longistyline A shows antimicrobial activity against *MRSA* with an MIC value of 1.56 μg/mL. Longistyline A shows neuroprotective effects, it can be used for the research of infection and nerve diseases .

HY-112959

Telavancin TD-6424	Antibiotic Bacterial	Infection
Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria .

HY-14737A

Ceftaroline fosamil hydrate 2 Publications Verification TAK-599 hydrate; PPI0903 hydrate	Antibiotic Bacterial	Infection
Ceftaroline fosamil hydrate is a potent cephalosporin antibiotic. Ceftaroline fosamil hydrateshows broad-spectrum activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae, and common Gram-negative organisms. Ceftaroline fosamil hydrate has anti-infective activity, and can be used for the research of complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia (CABP) .

HY-174985

Anti-MRSA agent 32	Bacterial	Infection
Anti-MRSA agent 32 (Compound 26) is an orally active and selective SaClpP (Staphylococcus aureus ClpP protease) activator with an EC₅₀ value of 0.98 μM. Anti-MRSA agent 32 activates SaClpP to abnormally degrade bacterial proteins, inhibiting the proliferation of Staphylococcus aureus. Anti-MRSA agent 32 promotes wound healing in a murine skin infection model. Anti-MRSA agent 32 is promising for research of infectious diseases such as methicillin-resistant Staphylococcus aureus (MRSA) infections .

HY-163984

Antibacterial agent 240	Bacterial	Infection
Antibacterial agent 240 (compound 62-7c) is an antibacterial agent that can target multidrug-resistant (MDR) *MRSA* strains. Antibacterial agent 240 showed high biosafety and potent anti-infection activity in mouse pneumonia and mouse wound models of MRSA infection .

HY-173225

MRSA/VRE-IN-1	Bacterial	Infection
MRSA/VRE-IN-1 (Compound 3e) is an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The MIC/MBC of MRSA/VRE-IN-1 against VRE is 3.6/7.3 µM, and against MRSA is 7.3/14.6 µM. MRSA/VRE-IN-1 can be used in the research of the anti-infection field .

HY-N3515

Multicaulisin	Bacterial	Infection
Multicaulisin, a new Diels-Alder type adduct from Morus multicaulis roots, potently effects against Staphylococcus aureus (MRSA) isolates. Multicaulisin is an antibacterial agent and has the potential for MRSA infections research .

HY-139679

Antibacterial agent 28	Bacterial	Infection
Antibacterial agent 28 is a potential antibacterial candidate for combating MRSA infections (MICs = 0.5–2 μg/mL).

HY-Z8025

Deprodone	Bacterial	Infection Inflammation/Immunology
Deprodone is an active compound. Deprodone inhibits key processes such as bacterial cell wall synthesis by interacting with the hydrolase and transferase proteins of methicillin-resistant Staphylococcus aureus (MRSA). Deprodone is used in research on anti-MRSA infection, inflammatory skin disorders, bowel disease, and fatty acid metabolism disorders .

HY-172826

Anti-MRSA agent 26	Bacterial	Infection
Anti-MRSA agent 26 is a potent *anti-MRSA* agent with MIC <0.015 μg/mL. Anti-MRSA agent 26 has superior activity against a broad range of Gram-positive pathogens and shows no cytotoxicity in three mammalian cell lines (Caco-2, DU-145 and MDCKII MDR1 cells) at 10 μM. Anti-MRSA agent 26 has a robust TAP pharmacophore and an excellent antibacterial activity in Staphylococcus aureus skin infection mice model .

HY-175295A

Anti-MRSA agent 33 iodide	Bacterial Reactive Oxygen Species (ROS)	Infection
Anti-MRSA agent 33 iodide is an anti-Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA) agent, with MIC values of 2-4 μg/mL. Anti-MRSA agent 33 iodide demonstrates effective biofilm eradication and minimal cytotoxicity toward mammalian cells. Anti-MRSA agent 33 iodide specifically binds to phosphatidylglycerol (PG) on bacterial membranes, leading to membrane disruption, excessive production of ROS, and metabolic collapse, ultimately resulting in bacterial cell death. Anti-MRSA agent 33 iodide reduces bacterial load in a murine skin infection model .

HY-175376

QPyN16Th	Antibiotic Bacterial	Infection
QPyN16Th is an N-palmitoylated cationic thiazolidine antibiotic. QPyN16Th is selectively active against the Gram-positive bavteria E. faecalis, S. aureus and MRSA with an MIC of 1.95 μM over gram-negative bacteria. QPyN16Th can induce membrane permeabilization and depolarization and ROS production in MRSA. QPyN16Th increases the survival of zebrafish model of intramuscular MRSA infection .

HY-173318

Anti-MRSA agent 25	Bacterial	Infection
Anti-MRSA agent 25 (Compound 10c) is an antibacterial agent with a MIC of 0.25 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 25 exerts its antibacterial activity by inhibiting biofilm formation, disrupting the cell wall (interacting with peptidoglycan and lipoteichoic acids), acting on the cell membrane (causing depolarization, increasing permeability, and disrupting integrity), reducing metabolic activity, interfering with cellular redox homeostasis, and binding to DNA. Anti-MRSA agent 25 is expected to be used in the research of the anti-infection field .

HY-178949

MRSA antibiotic 3	Antibiotic Bacterial DNA/RNA Synthesis	Infection
MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC₅₀ of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models .

HY-N16397

Anhydrofulvic acid	Bacterial	Infection
Anhydrofulvic acid is a polyketide with antibacterial activity (notably against MRSA, MIC=8 mg/mL). Anhydrofulvic acid is promising for research of Gram-positive infections (e.g., skin, bloodstream) .

HY-173478

OSUAB-0284	Topoisomerase Bacterial Antibiotic	Infection
OSUAB-0284 is a bacterial topoisomerase inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .

HY-N7111

Sultamicillin tosylate Sultamicillin (tosilate)	Bacterial Antibiotic	Infection
Sultamicillin tosylate is a broad-spectrum and orally active beta-lactamase inhibitor, an antibiotic with antibacterial activity .

HY-N7111R

Sultamicillin tosylate (Standard) Sultamicillin (tosilate) (Standard)	Reference Standards Bacterial Antibiotic	Infection
Sultamicillin (tosylate) (Standard) is the analytical standard of Sultamicillin (tosylate). This product is intended for research and analytical applications. Sultamicillin tosylate is a broad-spectrum and orally active beta-lactamase inhibitor, an antibiotic with antibacterial activity .

HY-P10345

OP-145	Bacterial	Infection
OP-145, an cathelicidin LL-37 derivative, is an antimicrobial peptide, and shows antibacterial activity against several MRSA strains. OP-145 can be used for research of chronic suppurative otitis media .

HY-105523

S 3578 sulfate	Bacterial	Infection
S 3578 (sulfate) is a broad-spectrum antibacterial agent, particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) (MIC = 0.78-3.13 μg/mL) and Pseudomonas aeruginosa (MIC = 1.56-6.25 μg/mL). S 3578 (sulfate) can be used in the research of infectious conditions .

HY-N7115R

Sultamicillin (Standard)	Reference Standards Bacterial Antibiotic	Infection
Sultamicillin (Standard) is the analytical standard of Sultamicillin. This product is intended for research and analytical applications. Sultamicillin is a broad-spectrum and orally active beta-lactamase inhibitor, an antibiotic with antibacterial activity .

HY-N7115

Sultamicillin	Bacterial Antibiotic	Infection
Sultamicillin is a broad-spectrum and orally active beta-lactamase inhibitor, an antibiotic with antibacterial activity .

HY-N15451

Deoxytopsentin	Pyruvate Kinase	Infection
Deoxytopsentin is a compound that can be found in marine sponges. It is an inhibitor of pyruvate kinase (PK) in methicillin-resistant Staphylococcus aureus (MRSA), with an IC₅₀ value of 240 nM. Deoxytopsentin can be used in research in the field of anti-infection .

HY-N15550

Armeniaspirol B	Antibiotic Bacterial	Infection
Armeniaspirol B is a selective antibiotic targeting Gram-positive pathogens, showing MIC values of 0.5 μg/mL against S. aureus Newman and 2.0 μg/mL against S. aureus USA300. Armeniaspirol B is promising for research of Gram-positive bacterial infections (e.g., MRSA, VRE infections) .

HY-156122

DHFR-IN-8	Dihydrofolate reductase (DHFR) Bacterial	Infection
DHFR-IN-8 (compound 6r) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-8 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC₅₀=15.6 ng/mL) in mouse models of systemic infection and thigh infection .

HY-174273

Antibacterial agent 280	Bacterial	Infection
Antibacterial agent 280 (Compound 7af) is an antibacterial agent targeting methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA). Antibacterial agent 280 is promising for research of is promising for research of S. aureus infections .

HY-146811

HSGN-94	Bacterial	Inflammation/Immunology
HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model .

HY-B0958

Mupirocin BRL-4910A; Pseudomonic acid	Bacterial Antibiotic Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-125747

Actinomycin X2 1 Publications Verification Actinomycin V	Bacterial Antibiotic Apoptosis	Infection Cancer
Actinomycin X2 (Actinomycin V), produced by many Streptomyces sp., shows strong inhibition of *MRSA* with a minimum inhibitory concentration (MIC) value of 0.25 μg/mL. Actinomycin X2 can be used for cancer and bacterial infection .

HY-W108875

Mupirocin lithium BRL-4910A lithium; Pseudomonic acid lithium	Antibiotic Bacterial Aminoacyl-tRNA Synthetase	Infection Endocrinology
Mupirocin lithium is an antibiotic. Mupirocin lithium inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin lithium has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin lithium can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis .

HY-10391

E-3709	Bacterial	Infection
E3709 is an antibacterial agent. E3709 exhibits significant inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA), Enterococcus faecalis, streptococci, Clostridia, and diphtheroids. E3709 can be used for research related to Gram-positive bacterial infections .

HY-163700

Fabl inhibitor 1	Bacterial	Infection
Fabl inhibitor 1 (Compound (S)-n31) is an orally active and potent SaFabI inhibitor (IC₅₀ = 94.0 nM, MIC = 0.25-1 μg/mL). Fabl inhibitor 1 can be used for the research of methicillin-resistant S. aureus (MRSA) infection .

HY-172813

Vancomycin prodrug	Bacterial Antibiotic Autophagy	Infection Cancer
Vancomycin prodrug (compound 13c) is a Vancomycin (HY-B0671) prodrug. Vancomycin prodrug shows antibacterial effect with MICs of 0.78 μM, 0.78 μM, 1.56 μM for S. aureus 330041, MRSA USA 300 and MRSA 3390, respectively. Vancomycin prodrug has the ability to quickly bind to Cys-34 residue of plasma. Vancomycin prodrug exhibits a good therapeutic effect on MRSA USA300 infected mice similar to Vancomycin. Vancomycin prodrug, an albumin-binding acid-sensitive prodrug, effectively reduces Vancomycin’s nephrotoxicity while maintaining its efficacy for Gram-positive bacterial infections .

HY-N16460

Albomycin δ2	Antibiotic Bacterial	Infection
Albomycin δ2 is a siderophore-antibiotic conjugate targeting bacterial ribosomes (MIC: 0.0625 μg/mL against S. pneumoniae, 0.125 μg/mL against MRSA). Albomycin δ2 is promising for research of Streptococcus pneumoniae and Staphylococcus aureus infections .

HY-175723

MAO-A/B-IN-4	Bacterial Monoamine Oxidase	Infection
MAO-A/B-IN-4 is an orally active MAO-A/B inhibitor, with IC₅₀ values of 51.3 μM and 47.0 μM, respectively. MAO-A/B-IN-4 exhibits potent activity against S. aureus, MSSA, MRSA, LRSA, and LREFa. MAO-A/B-IN-4 demonstrates potent antibacterial efficacy in a mouse model of LRSA peritonitis infection. MAO-A/B-IN-4 can be used for the study of bacterial infections .

Cat. No.	Product Name	Type

HY-69174

1-Amino-2,5-anhydro-1-deoxy-D-mannitol

Microbial Culture

1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.

Cat. No.	Product Name	Target	Research Area

HY-125747

Actinomycin X2 1 Publications Verification Actinomycin V	Bacterial Antibiotic Apoptosis	Infection Cancer
Actinomycin X2 (Actinomycin V), produced by many Streptomyces sp., shows strong inhibition of *MRSA* with a minimum inhibitory concentration (MIC) value of 0.25 μg/mL. Actinomycin X2 can be used for cancer and bacterial infection .

HY-P5545

Lynronne-1	Bacterial	Infection
Lynronne-1 is an antimicrobial peptide. Lynronne-1 is active against Gram-positive bacterials, including MDR strains (MIC: 8-32 μg/mL for methicillin-resistant MRSA strains). Lynronne-1 reduces the bacterial load in MRSA infected wound murine model. Lynronne-1 is also effective against P. aeruginosa infection .

HY-P5547

Lynronne-3	Bacterial	Infection
Lynronne-3 is an antimicrobial peptide. Lynronne-1 is active against Gram-positive bacterials, including MDR strains (MIC: 32-128 μg/mL for methicillin-resistant MRSA strains). Lynronne-3 is also effective against P. aeruginosa infection

HY-P5546

Lynronne-2	Bacterial	Infection
Lynronne-2 is an antimicrobial peptide. Lynronne-1 is active against Gram-positive bacterials, including MDR strains (MIC: 32-256 μg/mL for methicillin-resistant MRSA strains). Lynronne-2 is also effective against P. aeruginosa infection

HY-P10345

OP-145	Bacterial	Infection
OP-145, an cathelicidin LL-37 derivative, is an antimicrobial peptide, and shows antibacterial activity against several MRSA strains. OP-145 can be used for research of chronic suppurative otitis media .

HY-P4204

Ranalexin	Bacterial	Infection
Ranalexin is an antimicrobial peptide. Ranalexin inhibits S. aureus, E. coli, P. aerugiaosa with MICs of 4, 32, 128 μg/mL .

HY-P1405

Pam3CSK4-Biotin Pam3Cys-Ser-(Lys)4-Biotin	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
Pam3CSK4-Biotin is biotinylated Pam3CSK4. Pam3CSK4-Biotin is a Toll-like receptor 1/2 (TLR1/2) agonist .

HY-P1405A

Pam3CSK4-Biotin TFA Pam3Cys-Ser-(Lys)4-Biotin TFA	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
Pam3CSK4-Biotin (Pam3Cys-Ser-(Lys)4-Biotin) TFA is biotinylated Pam3CSK4. Pam3CSK4-Biotin TFA is a Toll-like receptor 1/2 (TLR1/2) agonist .

HY-P11085

WLBU2	Bacterial	Infection
WLBU2 is a engineered cationic antimicrobial peptide (eCAP) that overcomes the environmental sensitivity of natural antimicrobial peptides (AMPs). WLBU2 exhibits rapid bactericidal effect, with the MIC values of ≤ 10 μM against both Gram-negative and Gram-positive bacteria including MRSA, vancomycin-resistant enterococci, K. pneumoniae, E.aerogenes, E. cloacae, Escherichia coli, et, al. WLBU2 prevents P. aeruginosa biofilm growth and retains its activity in an environment rich in mucus, low pH and high salt concentrations without negative effects on human airway epithelial cells. WLBU2 can be used for the studies of cystic fibrosis (CF) and Pseudomonas aeruginosa infections .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks